DOCSLIB.ORG

Abstracts from the 5Th World Psoriasis & Psoriatic Arthritis Conference 2018

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Abstracts from the 5Th World Psoriasis & Psoriatic Arthritis Conference 2018 ISSN 0001-5555 ActaDV Volume 98 2018 Supplement No. 219 ADVANCES IN DERMATOLOGY AND VENEREOLOGY A Non-profit International Journal for Interdisciplinary Skin Research, Clinical and Experimental Dermatology and Sexually Transmitted Diseases Abstracts from the 5th World Psoriasis & Psoriatic Arthritis Conference 2018 Official Journal of June 27–30, 2018 - European Society for Dermatology and Psychiatry Affiliated with Stockholm, Sweden - The International Forum for the Study of Itch Immediate Open Access Acta Dermato-Venereologica www.medicaljournals.se/adv DV cta A enereologica V ermato- D cta A DV cta A dvances in dermatology and venereology A Abstracts from the 5th World Psoriasis & Psoriatic Arthritis Conference 2018 www.medicaljournals.se/acta doi: 10.2340/00015555-2978 Journal Compilation © 2018 Acta Dermato-Venereologica. Acta Derm Venereol 2018; Suppl 219 2 5th World Psoriasis & Psoriatic Arthritis Conference 2018 Ref.no Title Biomarkers and Imaging 001 A metagenomics study of the elbow of psoriasis subjects and their healthy relatives Clinical phenotypes 002 Nail disorders in patients with Psoriasis vulgaris 003 Psoriasis hidden in Gottron’s papules Comorbidities 004 Characteristics of psoriasis in obese patients versus non-obese patients; a multicenter study 005 Psoriasis and comorbidity 006 Risk of periodontal disease in patients with chronic plaque psoriasis 007 Splenomegaly and Psoriasis - A case report 008 Psoriasis as predictor for cardiovascular and metabolic comorbidity in middle-aged women 009 A Case of Concurrent Psoriasis and Vitiligo 010 Successful long-term double disease control by adalimumab in a patient with psoriasis vulgaris and hidradenitis suppurativa 011 Clinical and epidemiological caracterization of psoriasis and psoriatic arthritis on a multidisciplinary assesment model. 012 Alcohol and Psoriasis- a Prospective Swedish Study 013 ¨Psoriasis and Cancer. Retrospective study in the Psoriasis sector of the Dermatology Service at Ramos Mejia Hospital¨ 014 Hematological disorders in the patient with psoriatic arthritis treated with methotrexate and tumor necrosis alpha (TNFalpha) inhibitor 015 The relationship between psoriasis, comorbidities, and depression onset: A nationwide observational control study Current and new therapeutic modalities 016 Efficacy of Adalimumab plus Methotrexate in Patients with Moderate to Severe Plaque Psoriasis 018 Attainment of remission and minimal disease activity after starting methotrexate subcutaneous therap 019 Secukinumab in pregnancy: outcomes in psoriasis, psoriatic arthritis and ankylosing spondylitis from the global safety database 020 Ixekizumab improves impact of genital psoriasis on sexual activity: Results from a Phase 3b study 021 Dose optimization of Secukinumab in subjects with moderate to severe plaque psoriasis: OPTIMISE study 022 Inhibition of anti-TNF-alpha cytokine in the treatment of psoriasis and the analysis of infectious complications 023 Treatment use and satisfaction among patients with psoriasis and psoriatic arthritis in Scandinavia 024 First Patient-Reported Insights From a Multinational, Retrospective, Cross-Sectional Study of Real-World Experience of Psoriasis Patients Treated With Apremilast in Clinical Dermatology Practice (APPRECIATE) 025 Physician- and Patient-Reported Outcomes With Apremilast for Patients With Plaque Psoriasis During Routine Dermatology Care in Germany: A Second Interim Analysis 026 Improvements in Work Productivity With Up to 104 Weeks of Apremilast Monotherapy: Results From a Phase 3b, Randomized, Controlled Study in Biologic-Naive Subjects With Active Psoriatic Arthritis 027 Examining Disease Severity and Symptom Improvement With Patient and Physician Assessments: Results From a Phase IV Analysis of Apremilast in Patients With Moderate Plaque Psoriasis 028 Hemoglobin A1c and Weight Changes With Apremilast in Patients With Psoriasis and Psoriatic Arthritis: Pooled Laboratory Analysis of the Phase 3 ESTEEM and PALACE Trials 029 Canadian Humira Post-Marketing Observational Epidemiological Study Assessing the Effectiveness of Adalimumab vs Non-Biologic DMARDs in Psoriatic Arthritis (Complete-PsA): 12-Month Effectiveness Data 030 Secukinumab Efficacy in Patients with Active Psoriatic Arthritis: Meta-analysis of 4 Phase 3 Trials 031 Impact of adalimumab vs. non-biologic treatments on skin outcomes of psoriatic arthritis patients: real-world data from the COMPLETE Study 032 Ixekizumab Improves Nail and Skin Psoriasis through 52 Weeks of Treatment in Patients with Active Psoriatic Arthritis: Results from Two Randomized, Double-Blind, Phase 3, Clinical Trials (SPIRIT-P1 and SPIRIT-P2) 034 Ixekizumab Makes Therapeutic Thresholds Possible in Active Psoriatic Arthritis Patients: Results from SPIRIT Trials 035 The macrophage modulator MP1032 shows safety and efficacy in a human phase IIa study for the treatment of moderate-to-severe plaque psoriasis 036 Secukinumab Improves Signs and Symptoms of Psoriatic Arthritis: Results from a Phase 3 Study, FUTURE 5 037 Incidence of Inflammatory Bowel Disease In Patients Treated With Secukinumab: Pooled Analysis of 21 Randomised Controlled Phase 3/4 Clinical Trials of Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis 038 Analysis of the position of the fumaric acid esters in current European psoriasis guidelines 039 Secukinumab Provides Rapid and Sustained Resolution of Enthesitis in Psoriatic Arthritis Patients: Pooled Analysis of Two Phase 3 Studies, FUTURE 2 and FUTURE 3 041 Long-Term Safety of Adalimumab (HUMIRA) in Adult Patients From Global Clinical Trials Across Multiple Indications: An Updated Analysis in 29,987 Patients Representing 56,951 Patient-years 042 Clinical response after guselkumab treatment among adalimumab PASI 90 non- responders: Results from the VOYAGE 1 and 2 trials 043 Consistency of response by weight across subgroups of patients with psoriasis treated with guselkumab: Results from the VOYAGE 1 and 2 trials 044 Impact of Clinical Specialty Setting on Disease Management in Patients with Psoriatic Arthritis 045 Speed of response of guselkumab compared with adalimumab for the treatment of moderate-to-severe psoriasis: results through Week 24 from the phase 3, double-blinded, placebo- and active comparator-controlled VOYAGE 1 and VOYAGE 2 trials 046 Safety of Certolizumab Pegol over 48 Weeks in Chronic Plaque Psoriasis Phase 3 Trials 047 Secukinumab Provides Sustained Minimal Disease Activity (MDA) and Remission Related to Disease Activity Index for Psoriatic Arthritis (DAPSA): 2-year Results from a Phase 3 Study www.medicaljournals.se/acta List of Abstracts 3 048 Predictors of Response to Tildrakizumab for Moderate to Severe Chronic Plaque Psoriasis 049 Long-term efficacy of guselkumab treatment after drug withdrawal and retreatment in patients with moderate-severe plaque psoriasis: results from VOYAGE 2 050 Outcomes Associated with Achievement of Various Treatment Targets in Patients With Psoriatic Arthritis Receiving Adalimumab 051 Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: Three Year Results from a Phase 3 Study (SPIRIT-P1) 052 Incidence of Serious Gastrointestinal Events Among Tildrakizumab-Treated Patients With Psoriasis 053 Durable Reduction in Absolute PASI with Certolizumab Pegol in Patients with Chronic Plaque Psoriasis 054 Relationships Between Tildrakizumab Dose, Exposure, Efficacy and Safety in Psoriasis Phase 3 Studies 055 Long-Term Safety and Efficacy of Adalimumab from the Phase 3 Randomized, Placebo-Controlled Trial in Patients with Nail and Skin Psoriasis 056 Eight-Year Interim Results from the ESPRIT 10-Year Postmarketing Surveillance Registry of Adalimumab for Moderate to Severe Psoriasis 057 Durability of Response in Certolizumab Pegol-Treated Patients over 48 Weeks in CIMPASI-1 & 2 Trials 058 Primary Efficacy and Safety of Adalimumab in Nail Psoriasis From the First 26 Weeks of a Phase-3, Randomized, Placebo-Controlled Trial With Subanalysis in Patients With and Without Psoriatic Arthritis 059 Certolizumab Pegol Is Effective for Chronic Plaque Psoriasis Across Patient Subgroups 060 Discontinuation of Biologic Therapies in Chronic Plaque Psoriasis: A Retrospective Cohort 061 Incidence of Infections in Clinical Trials of Tildrakizumab for Moderate to Severe Plaque Psoriasis 062 Efficacy and Safety of Risankizumab: Results from Two Double-Blind, Placebo- and Ustekinumab-Controlled, Phase 3 Trials in Moderate- to-Severe Plaque Psoriasis 063 Efficacy and safety of guselkumab administered with a novel self-injection device for the treatment of moderate-to-severe psoriasis: Results from the Phase III ORION self-dose study through Week 16 064 Efficacy of Tildrakizumab in Etanercept Partial Responders or Nonresponders 065 Efficacy of Tildrakizumab in Moderate to Severe Psoriasis Patients With Prior Exposure to Apremilast 066 Risankizumab Efficacy/Safety in Moderate-to-Severe Plaque Psoriasis: 16-Week Results from IMMhance 067 Disease Severity and Efficacy Insights: Patient-Level PASI Scores in Tildrakizumab Psoriasis Trials 068 Sustained and Improved Efficacy of Tildrakizumab from Week 28 to Week 52 in Treating Moderate-to-Severe Plaque Psoriasis 070 Better Skin Clearance is Associated with Improved Quality of Life in Moderate-to-Severe Psoriasis Patients Treated with Tildrakizumab 071 Statistic review of psoriasis systematic therapies in North Greece 073 Pharmakovigilance of systemic antipsoritic drugs: an update from routine care 074 The Impact of Patient Requests on Psoriatic Arthritis Treatment Epidemiology
Load more

Recommended publications
  • Apremilast and Systemic Retinoid Combination Treatment for Moderate to Severe Palmoplantar Psoriasis
    CASE LETTER Apremilast and Systemic Retinoid Combination Treatment for Moderate to Severe Palmoplantar Psoriasis Tali Czarnowicki, MD, MSc; B. Peter Rosendorff, PhD; Mark G. Lebwohl, MD copy accumulating evidence suggests that it is accompanied PRACTICE POINTS by a multitude of systemic inflammatory comorbidities.5 • Palmoplantar psoriasis is challenging to treat and is This insight supports the concept of systemic treatment unresponsive to many modalities. for patients with moderate to severe psoriasis. As a • Combination, rotational, and sequential treatment chronic disease, psoriasis requires continuous therapy. approaches may minimize side effects and loss of The treatment approach should focus on achieving efficacy as well as enhance treatment responses. efficacynot and minimizing side effects. These goals can • Apremilast and acitretin combination therapy led to be achieved by combination, rotational, and sequential 90% skin improvement in a case of severe recalcitrant treatment approaches.6 Many therapeutic combinations palmoplantar psoriasis. have proven effective, using beneficially different mecha- nisms of action (MOAs) and toxicity profiles.7 We present a patient with moderate to severe recalcitrant palmo- Doplantar psoriasis who demonstrated improvement with To the Editor: combination therapy. Psoriasis is a chronic inflammatory papulosquamous skin A 50-year-old man presented with palmoplantar pso- disease affecting 2% to 3% of the population.1 Its patho- riasis of 7 years’ duration. His medical history included genesis is multifactorial, consisting of a disrupted skin mild hyperlipidemia treated with atorvastatin. Prior topi- barrier and dysregulated immune activation.2 cal treatments including calcipotriene, betamethasone A wide armamentarium of topical and systemic treat- dipropionate, and tacrolimus ointment did not result in ments targeting different aspects of the disease patho- improvement.
    [Show full text]
  • Nurse-Led Drug Monitoring Clinic Protocol for the Use of Systemic Therapies in Dermatology for Patients
    Group arrangements: Salford Royal NHS Foundation Trust (SRFT) Pennine Acute Hospitals NHS Trust (PAT) Nurse-led drug monitoring clinic protocol for the use of systemic therapies in dermatology for patients with inflammatory dermatoses Lead Author: Dawn Lavery Dermatology Advanced Nurse Practitioner Additional author(s) N/A Division/ Department:: Dermatology, Clinical Support and Tertiary Medicine Applies to: (Please delete) Salford Royal Care Organisation Approving Committee Dermatology clinical governance committee Salford Royal Date approved: 13 February 2019 Expiry date: February 2022 Contents Contents Section Page Document summary sheet 1 Overview 2 2 Scope & Associated Documents 2 3 Background 3 4 What is new in this version? 3 5 Policy 4 Drugs monitored by nurses 4 Acitretin 7 Alitretinoin Toctino 11 Apremilast 22 Azathioprine 26 Ciclosporin 29 Dapsone 34 Fumaric Acid Esters – Fumaderm and Skilarence 36 Hydroxycarbamide 39 Hydroxychloroquine 43 Methotrexate 50 Mycophenolate moefetil 57 Nurse-led drug monitoring clinic protocol for the use of systemic therapies in dermatology for patients with inflammatory dermatoses Reference Number GSCDerm01(13) Version 3 Issue Date: 11/06/2019 Page 1 of 77 It is your responsibility to check on the intranet that this printed copy is the latest version Standards 67 6 Roles and responsibilities 67 7 Monitoring document effectiveness 67 8 Abbreviations and definitions 68 9 References 68 10 Appendices N/A 11 Document Control Information 71 12 Equality Impact Assessment (EqIA) screening tool 73 Group arrangements: Salford Royal NHS Foundation Trust (SRFT) Pennine Acute Hospitals NHS Trust (PAT) 1. Overview (What is this policy about?) The dermatology directorate specialist nurses are responsible for ensuring prescribing and monitoring for patients under their care, is in accordance with this protocol.
    [Show full text]
  • Australian Public Assessment Report for Apremilast
    Australian Public Assessment Report for Apremilast Proprietary Product Name: Otezla Sponsor: Celgene Pty Ltd October 2015 Therapeutic Goods Administration About the Therapeutic Goods Administration (TGA) · The Therapeutic Goods Administration (TGA) is part of the Australian Government Department of Health and is responsible for regulating medicines and medical devices. · The TGA administers the Therapeutic Goods Act 1989 (the Act), applying a risk management approach designed to ensure therapeutic goods supplied in Australia meet acceptable standards of quality, safety and efficacy (performance), when necessary. · The work of the TGA is based on applying scientific and clinical expertise to decision- making, to ensure that the benefits to consumers outweigh any risks associated with the use of medicines and medical devices. · The TGA relies on the public, healthcare professionals and industry to report problems with medicines or medical devices. TGA investigates reports received by it to determine any necessary regulatory action. · To report a problem with a medicine or medical device, please see the information on the TGA website <https://www.tga.gov.au>. About AusPARs · An Australian Public Assessment Report (AusPAR) provides information about the evaluation of a prescription medicine and the considerations that led the TGA to approve or not approve a prescription medicine submission. · AusPARs are prepared and published by the TGA. · An AusPAR is prepared for submissions that relate to new chemical entities, generic medicines, major variations, and extensions of indications. · An AusPAR is a static document, in that it will provide information that relates to a submission at a particular point in time. · A new AusPAR will be developed to reflect changes to indications and/or major variations to a prescription medicine subject to evaluation by the TGA.
    [Show full text]
  • Prior Authorization Inflammatory Conditions – Otezla® (Apremilast Tablets)
    Cigna National Formulary Coverage Policy Prior Authorization Inflammatory Conditions – Otezla® (apremilast tablets) Table of Contents Product Identifier(s) National Formulary Medical Necessity ................ 1 42932 Conditions Not Covered....................................... 2 Background .......................................................... 3 References .......................................................... 4 Revision History ................................................... 4 INSTRUCTIONS FOR USE The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer’s particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a customer’s benefit plan document may contain a specific exclusion related to a topic addressed in a Coverage Policy. In the event of a conflict, a customer’s benefit plan document always supersedes the information in the Coverage Policies. In the absence of a controlling federal or state coverage mandate, benefits are ultimately determined by the terms of the applicable benefit plan document. Coverage determinations in each specific instance require consideration of 1) the terms of the applicable benefit plan document in effect on the date of service; 2) any applicable laws/regulations; 3) any relevant collateral source materials including Coverage Policies and; 4) the specific facts of the particular situation.
    [Show full text]
  • Simponi Aria (Golimumab)
    Simponi Aria (golimumab) Simponi Aria is a tumor necrosis factor (TNF) blocker indicated for the treatment of adult patients with: ● Moderately to severely active Rheumatoid Arthritis (RA) in combination with methotrexate ● Active Psoriatic Arthritis (PsA) ● Active Ankylosing Spondylitis (AS) Simponi Aria will be considered for coverage when ALL of the criteria below are met and ​ confirmed with supporting medical documentation. I. Criteria for Initial Approval Rheumatoid Arthritis (RA) ● Patient is 18 years old or older. ● Must be prescribed by, or in consultation with, a specialist in rheumatology. ● Documentation of moderate to severe active disease; AND ​ ○ Patient has failed previous therapy with a oral disease modifying antirheumatic agent (DMARD) such as methotrexate, azathioprine, auranofin, hydroxychloroquine, penicillamine, sulfasalazine, or leflunomide. ● Documentation that pretreatment screening has occurred; ○ Documentation that the patient has been evaluated and screened for the presence of hepatitis B virus (HBV) prior to initiating treatment, AND ​ ​ ○ Patient has been evaluated and screened for the presence of latent tuberculosis (TB) infection prior to initiating treatment and will receive ongoing monitoring for presence of TB during treatment, AND ​ ○ Patient does not have any evidence of active infection, including clinically important localized infections. ● Prescribed in combination with methotrexate, unless contraindicated. ● Must not be administered concurrently with live vaccines. ​ ​ 1 ● Patient is not on concurrent
    [Show full text]
  • Apremilast, an Oral Phosphodiesterase 4 (PDE4) Inhibitor: a Novel Treatment Option for Nurse Practitioners Treating Patients
    SUPPLEMENT ARTICLE Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor: A novel treatment option for nurse practitioners treating patients with psoriatic disease Melodie Young, MSN, A/GNP-BC, DcNP (Nurse Practitioner)1,2 & Heather L. Roebuck, DNP, FNP-BC, FAANP (Nurse Practitioner)3 1Modern Dermatology–Aesthetics Center Dallas, Dallas, Texas 2Modern Research Associates, Dallas, Texas 3RoebuckDERM, West Bloomfield, Michigan Keywords Abstract Dermatology; psoriasis; medications; patient; treatment. Background and purpose: Apremilast is an oral nonbiologic medication ap- proved for the treatment of adult patients with active psoriatic arthritis and for Correspondence patients with moderate to severe plaque psoriasis. This article summarizes the ef- Melodie Young, MSN, A/GNP-BC, DcNP, Modern ficacy and safety of apremilast and provides characterization of the novel medica- Dermatology–Aesthetics Center Dallas, 9101 N tion with clinical perspectives to successfully incorporate this therapy into prac- Central Expy # 160, Dallas, TX 75231. tice for appropriate patients. Tel: 214-265-1818; Fax: 214-265-1806; Data sources: A review and synthesis of the results from the ESTEEM (Efficacy E-mail: [email protected] and Safety Trial Evaluating the Effects of Apremilast in Psoriasis) phase 3 clin- Received: 5 May 2016; ical studies evaluating the efficacy, safety, and tolerability of apremilast for the revised: 9 September 2016; treatment of moderate to severe plaque psoriasis was conducted. accepted: 14 September 2016 Conclusions: Results from the
    [Show full text]
  • Early and Sustained Efficacy with Apremilast Monotherapy in Biological-Naïve Patients with Psoriatic Arthritis
    ARD Online First, published on January 17, 2018 as 10.1136/annrheumdis-2017-211568 Clinical and epidemiological research Ann Rheum Dis: first published as 10.1136/annrheumdis-2017-211568 on 17 January 2018. Downloaded from EXTENDED REPORT Early and sustained efficacy with apremilast monotherapy in biological-naïve patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE) Peter Nash,1 Kamal Ohson,2 Jessica Walsh,3 Nikolay Delev,4 Dianne Nguyen,4 Lichen Teng,4 Juan J Gómez-Reino,5 Jacob A Aelion,6 on behalf of the ACTIVE investigators Handling editor Tore K Kvien ABSTRacT antirheumatic drugs (csDMARDs), but safety moni- Objective Evaluate apremilast efficacy across ariousv toring and risks may limit their long-term use.2 3 ► Additional material is The efficacy and safety of apremilast, an oral published online only. To view psoriatic arthritis (PsA) manifestations beginning at week please visit the journal online 2 in biological-naïve patients with PsA. phosphodiesterase 4 inhibitor, were demonstrated (http:// dx. doi. org/ 10. 1136/ Methods Patients were randomised (1:1) to apremilast in patients with active PsA in four phase III, annrheumdis- 2017- 211568). 30 mg twice daily or placebo. At week 16, patients placebo-controlled studies as part of the Psoriatic 1 whose swollen and tender joint counts had not improved Arthritis Long-term Assessment of Clinical Efficacy Department of Medicine, 4–7 University of Queensland, by ≥10% were eligible for early escape. At week 24, all (PALACE) clinical trial programme. The PALACE Brisbane, Queensland, Australia patients received apremilast through week 52. 1, 2 and 3 studies evaluated apremilast in patients 2Memorial University of Results Among 219 randomised patients (apremilast: with prior exposure to csDMARDs and/or biolog- Newfoundland, St.
    [Show full text]
  • Otezla® (Apremilast) P&T Approval Date 5/2014, 10/2014, 2/2015, 3/2016, 3/2017, 3/2018, 3/2019, 3/2020, 3/2021 Effective Date 6/1/2021; Oxford Only: 6/1/2021
    UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2021 P 1129-10 Program Prior Authorization/Notification Medication Otezla® (apremilast) P&T Approval Date 5/2014, 10/2014, 2/2015, 3/2016, 3/2017, 3/2018, 3/2019, 3/2020, 3/2021 Effective Date 6/1/2021; Oxford only: 6/1/2021 1. Background: Otezla® (apremilast) is a phosphodiesterase 4 (PDE4) inhibitor indicated for the treatment of adult patients with active psoriatic arthritis, for the treatment of patients with moderate to severe plaque psoriasis for whom phototherapy or systemic therapy is appropriate, and for the treatment of adult patients with oral ulcers associated with Behçet’s disease.1 2. Coverage Criteria: A. Psoriatic Arthritis (PsA) 1. Initial Authorization a. Otezla will be approved based on both of the following criteria: (1) Diagnosis of active psoriatic arthritis -AND- (2) Patient is not receiving Otezla in combination with either of the following: (a) Biologic DMARD [e.g., Enbrel (etanercept), Humira (adalimumab), Simponi (golimumab), Orencia (abatacept)] (b) Janus kinase inhibitor [e.g., Xeljanz (tofacitinib)] Authorization will be issued for 12 months. 2. Reauthorization a. Otezla will be approved based on both of the following criteria: (1) Documentation of positive clinical response to Otezla therapy -AND- (2) Patient is not receiving Otezla in combination with either of the following: © 2021 UnitedHealthcare Services, Inc. 1 (a) Biologic DMARD [e.g., Enbrel (etanercept), Humira (adalimumab), Simponi (golimumab), Orencia (abatacept)] (b) Janus kinase inhibitor [e.g., Xeljanz (tofacitinib)] Authorization will be issued for 12 months. B. Plaque Psoriasis 1. Initial Authorization a. Otezla will be approved based on both of the following criteria: (1) Diagnosis of moderate to severe plaque psoriasis for whom phototherapy or systemic therapy is appropriate.
    [Show full text]
  • Review Proposal of TA433; Apremilast for Treating Active Psoriatic Arthritis (Rapid Review TA372), TA445; Certolizumab Pegol
    Review proposal of TA433; Apremilast for treating active psoriatic arthritis (rapid review TA372), TA445; Certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease modifying anti-rheumatic drugs TA433 was published in February 2017 and scheduled to be considered for review in 2020. TA445 was published in May 2017 and scheduled to be considered for review in 2020. 1. Proposal We propose that TA433 and TA445 are transferred to the ‘static’ guidance list. 2. Rationale We did not identify any new clinical evidence that would change the existing recommendations in TA433 and TA445. There are no changes to the marketing authorisations or the prices. There is no new evidence on comparative effectiveness for certolizumab pegol, secukinumab, or apremilast compared with biologics or each other for treating psoriatic arthritis. 3. Summary of new evidence and implications for review Has there been any change to the price of the technology(ies) since the guidance was published? There are no changes to the list prices of apremilast, certolizumab pegol and secukinumab since the publication of TA433 and TA445. ************************************************************************************************ *****************************************************************************. Biosimilars There are now biosimilar versions of adalimumab, etanercept and infliximab for treating psoriatic arthritis. TA445, which was published in May 2017, included biosimilars of etanercept and infliximab while TA433, which was published in February 2017, did not. In addition, there have been changes to comparator prices paid by the NHS (specific values are not reported here as these are confidential). The patents for tocilizumab and for certolizumab pegol expire in 2019 and 2021 respectively and biosimilars for these are in development.
    [Show full text]
  • Anatomical Classification Guidelines V2020 EPHMRA ANATOMICAL
    EPHMRA ANATOMICAL CLASSIFICATION GUIDELINES 2020 Anatomical Classification Guidelines V2020 "The Anatomical Classification of Pharmaceutical Products has been developed and maintained by the European Pharmaceutical Marketing Research Association (EphMRA) and is therefore the intellectual property of this Association. EphMRA's Classification Committee prepares the guidelines for this classification system and takes care for new entries, changes and improvements in consultation with the product's manufacturer. The contents of the Anatomical Classification of Pharmaceutical Products remain the copyright to EphMRA. Permission for use need not be sought and no fee is required. We would appreciate, however, the acknowledgement of EphMRA Copyright in publications etc. Users of this classification system should keep in mind that Pharmaceutical markets can be segmented according to numerous criteria." © EphMRA 2020 Anatomical Classification Guidelines V2020 CONTENTS PAGE INTRODUCTION A ALIMENTARY TRACT AND METABOLISM 1 B BLOOD AND BLOOD FORMING ORGANS 28 C CARDIOVASCULAR SYSTEM 35 D DERMATOLOGICALS 50 G GENITO-URINARY SYSTEM AND SEX HORMONES 57 H SYSTEMIC HORMONAL PREPARATIONS (EXCLUDING SEX HORMONES) 65 J GENERAL ANTI-INFECTIVES SYSTEMIC 69 K HOSPITAL SOLUTIONS 84 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS 92 M MUSCULO-SKELETAL SYSTEM 102 N NERVOUS SYSTEM 107 P PARASITOLOGY 118 R RESPIRATORY SYSTEM 120 S SENSORY ORGANS 132 T DIAGNOSTIC AGENTS 139 V VARIOUS 141 Anatomical Classification Guidelines V2020 INTRODUCTION The Anatomical Classification was initiated in 1971 by EphMRA. It has been developed jointly by Intellus/PBIRG and EphMRA. It is a subjective method of grouping certain pharmaceutical products and does not represent any particular market, as would be the case with any other classification system.
    [Show full text]
  • Medical Dermatology Update OCTOBER 11, 2018
    Medical Dermatology Update OCTOBER 11, 2018 FRANCISCA KARTONO, DO, FAAD DERMATOLOGY SPECIALISTS OF CANTON, MI DERMATOLOGY SPECIALISTS OF BRIGHTON, MI I have no relevant disclosures Will discuss off-label use of medications Outline Selected topics in Dermatology in the world of : 1. Atopic eczema 2. Psoriasis 3. Hidradenitis Suppurativa 4. Non-surgical treatment of NMSC: eBx 5. Photomedicine Atopic dermatitis review Most common skin disease in general population/ humans 7% adults and 15-25% children in US Age of onset : 85% are diagnosed by the age of 5 Strong genetic component (30%). Not all explained by FLG mutation. Need for new agents to control the disease is unmet. Majority treatment options for moderate to severe disease are still off-label Complex interplay of epidermal skin barrier dysfunction , atopic march , immune pathways & environmental factors Need multipronged approach J Invest Dermatol. 2015 Jan;135(1):56-66 ] Drucker AM. Allergy Asthma Proc. 2017;38:3–8. Pediatric allergy and immunology. 2013;24(5):476-486. Bieber T. Ann Dermatol. 2010;22:125–137. Journal of clinical sleep medicine. 2010;6(6):581-588. SilverbergJI,SimpsonEL. Pediatr Allergy Immunol. 2013;24:476–486. Pediatric dermatology. 2009;26(2):143-149. https://nationaleczema.org/eczema/ Pediatrics. Sep 2004;114(3):607-611. AD: Guidelines of care Latest AAD Guidelines of treatment from 2014 : Pre-crisaborole,& dupilumab Updated Guidelines AD guidelines article Ann Aller Asthma Immunol 120(2018): 10-22 Prevention of AD Effective skin emollients since birth may prevent exposure to AD triggers, bacteria, microbes Emolients from birth can prevent AD ? 2 prospective RCT , showed 50% reduction in risk for eczema by 6-8 months of age.
    [Show full text]
  • Cosentyx - ARIZONA
    Clinical Pharmacy Program Guidelines for Cosentyx - ARIZONA Program Prior Authorization Medication Cosentyx (secukinumab) Markets in Scope Arizona 1. Background: Cosentyx (secukinumab) is a human interleukin-17A antagonist indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy. It is also indicated for the treatment of adult patients with active psoriatic arthritis, active non-radiographic axial spondyloarthritis with objective signs of inflammation or active ankylosing spondylitis. 2. Coverage Criteria: A. Plaque Psoriasis 1. Initial Authorization One of the following: (1) All of the following: a. Diagnosis of moderate to severe plaque psoriasis -AND- b. Greater than or equal to 3% body surface area involvement, palmoplantar, facial, or genital involvement, or severe scalp psoriasis -AND- c. Both of the following: (1) History of failure to one of the following topical therapies unless contraindicated or clinically significant adverse effects are experienced (document date, and duration of trial): . Corticosteroids (e.g., betamethasone, clobetasol, desonide) . Vitamin D analogs (e.g., calcitriol, calcipotriene) . Tazarotene . Calcineurin inhibitors (e.g., tacrolimus, pimecrolimus) . Anthralin Confidential and Proprietary, © 2019 UnitedHealthcare Services Inc. 1 . Coal tar -AND- (2) History of failure to a 3 month trial of methotrexate at the maximally indicated dose within the last 6 months, unless contraindicated or clinically significant adverse effects are experienced (document date, and duration of trial) d. Patient is not receiving Cosentyx in combination with any of the following: i. Biologic DMARD [e.g., Humira (adalimumab), Cimzia (certolizumab), Simponi (golimumab), Taltz (ixekizumab), Orencia (abatacept)] ii. Janus kinase inhibitor [e.g., Xeljanz (tofacitinib)] iii.
    [Show full text]